FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy
For immediate release: June 20, 2024 Today, the US Food and Drug Administration extended the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in DMD gene. Elevidys was previously approved … Read more